InvestSMART

Rhythm Biosciences Limited (ASX: RHY) - Announcements

- Current share price for RHY : $0.081

ASX company news and announcements for Rhythm Biosciences Limited (RHY) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Rhythm Biosciences Limited (RHY) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Rhythm Biosciences Limited (RHY), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Rhythm Biosciences Limited (RHY)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$29 Cleansing Notice 27 Aug 2025 9:33AM $0.098 $0.081 fallen by 17.35%
$29 Application for quotation of securities - RHY 27 Aug 2025 9:26AM $0.098 $0.081 fallen by 17.35%
$29 ColoSTAT Kit Validation Completion and NATA Submission 26 Aug 2025 9:22AM $0.105 $0.081 fallen by 22.86%
$29 Placement Prospectus 18 Aug 2025 12:44PM $0.110 $0.081 fallen by 26.36%
$29 Placement Issue Investor Presentation 18 Aug 2025 9:33AM $0.105 $0.081 fallen by 22.86%
$29 Proposed issue of securities - RHY 18 Aug 2025 9:33AM $0.105 $0.081 fallen by 22.86%
$29 Proposed issue of securities - RHY 18 Aug 2025 9:33AM $0.105 $0.081 fallen by 22.86%
$29 Share Placement to Raise Up To $3.75 million 18 Aug 2025 9:33AM $0.105 $0.081 fallen by 22.86%
$29 Trading Halt 14 Aug 2025 8:28AM $0.105 $0.081 fallen by 22.86%
$29 Change in substantial holding 8 Aug 2025 7:25PM $0.105 $0.081 fallen by 22.86%
$29 Response to ASX Price Query 6 Aug 2025 2:36PM $0.145 $0.081 fallen by 44.14%
$29 ColoSTAT Kits Deliver Breakthrough Results 4 Aug 2025 9:11AM $0.060 $0.081 risen by 35%
$29 Notification of cessation of securities - RHY 1 Aug 2025 4:46PM $0.060 $0.081 risen by 35%
$29 Notification regarding unquoted securities - RHY 1 Aug 2025 4:42PM $0.060 $0.081 risen by 35%
$29 Jun 25 Quarterly Activities Report and Appendix 4C 31 Jul 2025 9:07AM $0.056 $0.081 risen by 44.64%
$29 Genetype MSK Research Collaboration 24 Jul 2025 9:07AM $0.053 $0.081 risen by 52.83%
$29 Strategic Genetype Pilot with Leading Australian Pathology 17 Jul 2025 8:47AM $0.057 $0.081 risen by 42.11%
$29 Change of Director's Interest Notice - Otto Buttula 9 Jul 2025 5:20PM $0.057 $0.081 risen by 42.11%
$29 Change in substantial holding - Otto Buttula 9 Jul 2025 4:43PM $0.057 $0.081 risen by 42.11%
$29 Change in substantial holding 3 Jul 2025 5:12PM $0.052 $0.081 risen by 55.77%
$29 FY2025 R&D Tax Incentive Loan Funding 30 Jun 2025 5:28PM $0.054 $0.081 risen by 50%
$29 NATA Accreditation Awarded for Genetype Laboratory 24 Jun 2025 9:16AM $0.060 $0.081 risen by 35%
$29 Ceasing to be a substantial holder 23 Jun 2025 4:35PM $0.060 $0.081 risen by 35%
$29 Board Composition Update Succession Plan 23 Jun 2025 9:09AM $0.062 $0.081 risen by 30.65%
$29 Overview of Genetype Presentation 19 Jun 2025 9:12AM $0.060 $0.081 risen by 35%

101 - 125 of 639 results

Page 5 of 26

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.